The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment
Open accessAbstract
BACKGROUND Carbapenem-resistant Acinetobacter baumannii (CRAB) has gained global notoriety as a critically important nosocomial pathogen. It mostly affects debilitated patients, causing pneumonia and bloodstream infections with high mortality rates. Difficulties in treating CRAB infections stem from a formidable resistance profile that leaves available only a few antibiotics of uncertain efficacy such as colistin and tigecycline. Despite the relentless attempts to improve therapeutic approaches (as depicted in colistin-oriented randomized clinical trials and the numerous observational studies), progress is still limited. AIMS We aim (a) to assist physicians to adapt therapeutic approaches in CRAB infections by considering all potentially available antimicrobials, and (b) to present directions for future investigations that emerge through treatment efforts in endemic settings. SOURCES Articles and reviews from PubMed and Scopus databases; studies from ClinicalTrials.gov; presentations from ECCMID congresses and IDWeek meetings. CONTENT The review provides a succinct overview of the important pharmacokinetic/pharmocodynamic parameters of relevant antimicrobial agents, a critical appraisal of randomized control trials and observational studies, suggestions for increasing the strength of observational studies and directions facilitating the choice of therapeutic regimens by severity of infection and status of the host. IMPLICATIONS The lack of an optimal therapeutic regimen for CRAB thus far, as shown in this review, suggests the need to thoroughly investigate alternative approaches through carefully designed trials that should include all relevant drugs. Some of these alternative directions are indicated in the present review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Dosing guidance for intravenous colistin in critically-ill patients.
Nation, R. L., Garonzik, S. M., Thamlikitkul, V., Giamarellos-Bourboulis, E. J., Forrest, A., Paterson, D. L., Li, J., & Silveira, F. P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw839 · Cited by 262
Cited by
Acinetobacter baumannii Antibiotic Resistance Mechanisms
Kyriakidis, I., Vasileiou, E., Pana, Z. D., & Tragiannidis, A. (2021) · Pathogens · doi:10.3390/pathogens10030373 · Cited by 678
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
Jean, S.-S., Harnod, D., & Hsueh, P.-R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.823684 · Cited by 366
A novel antibiotic class targeting the lipopolysaccharide transporter
Zampaloni, C., Mattei, P., Bleicher, K., Winther, L., Thäte, C., Bucher, C., Adam, J.-M., Alanine, A., Amrein, K. E., Baidin, V., et al. (2024) · Nature · doi:10.1038/s41586-023-06873-0 · Cited by 308
Mezcord, V., Escalante, J., Nishimura, B., Traglia, G. M., Sharma, R., Valle, Q., Tuttobene, M. R., Subils, T., Marin, I., Pasterán, F., et al. (2023) · doi:10.20944/preprints202306.0950.v1 · Cited by 27
Metadata
- Authors
- Piperaki, E.-T., Tzouvelekis, L. S., Miriagou, V., & Daikos, G. L.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 25
- Issue
- 8
- Pages
- 951-957
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2925136326
- Cited by
- 240
- References
- 3
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. https://app.cochat.ai/papers/10.1016/j.cmi.2019.03.014
- The paper
- Piperaki, E.-T., Tzouvelekis, L. S., Miriagou, V., & Daikos, G. L. (2019). Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2019.03.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.